Pfizer Inc. (NYSE:PFE) Stock Position Decreased by Pinnacle Wealth Planning Services Inc.

Pinnacle Wealth Planning Services Inc. cut its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 50.7% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 14,701 shares of the biopharmaceutical company's stock after selling 15,132 shares during the quarter. Pinnacle Wealth Planning Services Inc.'s holdings in Pfizer were worth $390,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in PFE. Patriot Financial Group Insurance Agency LLC raised its position in Pfizer by 1.0% in the fourth quarter. Patriot Financial Group Insurance Agency LLC now owns 38,706 shares of the biopharmaceutical company's stock valued at $1,027,000 after purchasing an additional 391 shares during the period. D Orazio & Associates Inc. lifted its stake in shares of Pfizer by 5.5% in the fourth quarter. D Orazio & Associates Inc. now owns 7,549 shares of the biopharmaceutical company's stock worth $200,000 after acquiring an additional 391 shares in the last quarter. Lipe & Dalton boosted its holdings in Pfizer by 17.7% in the fourth quarter. Lipe & Dalton now owns 2,659 shares of the biopharmaceutical company's stock valued at $71,000 after purchasing an additional 400 shares during the last quarter. Beam Wealth Advisors Inc. increased its holdings in Pfizer by 1.5% during the 4th quarter. Beam Wealth Advisors Inc. now owns 27,444 shares of the biopharmaceutical company's stock worth $728,000 after purchasing an additional 401 shares during the last quarter. Finally, Providence Capital Advisors LLC raised its position in shares of Pfizer by 0.4% in the 4th quarter. Providence Capital Advisors LLC now owns 114,358 shares of the biopharmaceutical company's stock valued at $3,034,000 after purchasing an additional 409 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. Cantor Fitzgerald assumed coverage on shares of Pfizer in a research report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 target price for the company. UBS Group increased their target price on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. The Goldman Sachs Group reiterated a "neutral" rating and issued a $25.00 price target (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Finally, Guggenheim restated a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, four have issued a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $29.17.

Pfizer Stock Performance

Shares of NYSE:PFE traded up $0.26 during trading hours on Thursday, hitting $23.44. The stock had a trading volume of 26,047,028 shares, compared to its average volume of 41,037,967. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54. The firm has a market capitalization of $133.26 billion, a price-to-earnings ratio of 16.62, a PEG ratio of 0.64 and a beta of 0.58. The stock's fifty day simple moving average is $23.22 and its 200 day simple moving average is $25.11. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. The company had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. Pfizer's revenue was down 7.8% on a year-over-year basis. During the same period in the previous year, the firm earned $0.82 EPS. Sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 7.34%. The ex-dividend date is Friday, May 9th. Pfizer's payout ratio is 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.